Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS1191-0445 in Severe Hemophilia A
NCT07548411Phase 2Active, not recruiting
- Sponsor
- Gritgen Therapeutics Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GS001 in hemophilia A, sponsored by Gritgen Therapeutics Co., Ltd. Primary endpoints: Adverse Events at 5 years, Thrombosis Risk at 5 years and 8 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
GS001
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07548411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548411.